Real-world safety comparison of liraglutide and semaglutide in weight management: Insights from European pharmacovigilance data.

Ruggiero R, Longo M, Mascolo A, Di Nuzzo M, Laino LV, Caruso P, D'Amato R, Rafaniello C, Maiorino MI, Esposito K, Capuano A

European journal of pharmacology25 Jul 2025Cited by 3 (Europe PMC)

PMID40716637DOI10.1016/j.ejphar.2025.178004PepBankPUB-40716637

Publisher page PubMedAsk about this study

Jump to 25 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study25

5 results from studies that gave the peptide. 5 results from people.

01HumanObservational studySafety outcome
In European pharmacovigilance reports for weight management, liraglutide was associated with higher reported pancreatitis frequency; the abstract did not specify the original reporting reference.
In plain wordsIn weight-management safety reports, liraglutide was linked to higher pancreatitis reporting; the exact reporting comparison was unstated.
Peptide
Liraglutide
Outcome
Increasepancreatitis reporting frequency
Study
n: not reported in source
Outcome group
Adverse events · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
Disproportionality analysis revealed that liraglutide was associated with a higher reporting frequency of pancreatitis, gallbladder disorders, and thyroid tumors, while semaglutide showed a greater likelihood of vomiting and abdominal pain.
3 context sentences(design, population, supporting numbers)
Summary · context
A retrospective case-non-case study was conducted using data from the EudraVigilance database.
Summary · context
All cases involving liraglutide or semaglutide used for weight management and collected in the database between January 2018 and December 2023 were analyzed.
Summary · context
Disproportionality analysis was performed to assess the reporting odds ratios for events of interest (gastrointestinal events, pancreatitis, gallbladders disorders, psychiatric events, and gallbladder, pancreatic or thyroid tumors) reported at least three times.
Report a problemFND-4071663701
02HumanObservational studySafety outcome
In European pharmacovigilance reports for weight management, liraglutide was associated with higher reported gallbladder disorders frequency; the abstract did not specify the original reporting reference.
In plain wordsIn weight-management safety reports, liraglutide was linked to higher gallbladder disorders reporting; the exact reporting comparison was unstated.
Peptide
Liraglutide
Outcome
Increasegallbladder disorder reporting frequency
Study
n: not reported in source
Outcome group
Adverse events · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
Disproportionality analysis revealed that liraglutide was associated with a higher reporting frequency of pancreatitis, gallbladder disorders, and thyroid tumors, while semaglutide showed a greater likelihood of vomiting and abdominal pain.
3 context sentences(design, population, supporting numbers)
Summary · context
A retrospective case-non-case study was conducted using data from the EudraVigilance database.
Summary · context
All cases involving liraglutide or semaglutide used for weight management and collected in the database between January 2018 and December 2023 were analyzed.
Summary · context
Disproportionality analysis was performed to assess the reporting odds ratios for events of interest (gastrointestinal events, pancreatitis, gallbladders disorders, psychiatric events, and gallbladder, pancreatic or thyroid tumors) reported at least three times.
Report a problemFND-4071663702
03HumanObservational studySafety outcome
In European pharmacovigilance reports for weight management, liraglutide was associated with higher reported thyroid tumors frequency; the abstract did not specify the original reporting reference.
In plain wordsIn weight-management safety reports, liraglutide was linked to higher thyroid tumors reporting; the exact reporting comparison was unstated.
Peptide
Liraglutide
Outcome
Increasethyroid tumor reporting frequency
Study
n: not reported in source
Outcome group
Adverse events · Cancer
Studied dose
Dose not stated
Source sentences
Summary
Disproportionality analysis revealed that liraglutide was associated with a higher reporting frequency of pancreatitis, gallbladder disorders, and thyroid tumors, while semaglutide showed a greater likelihood of vomiting and abdominal pain.
3 context sentences(design, population, supporting numbers)
Summary · context
A retrospective case-non-case study was conducted using data from the EudraVigilance database.
Summary · context
All cases involving liraglutide or semaglutide used for weight management and collected in the database between January 2018 and December 2023 were analyzed.
Summary · context
Disproportionality analysis was performed to assess the reporting odds ratios for events of interest (gastrointestinal events, pancreatitis, gallbladders disorders, psychiatric events, and gallbladder, pancreatic or thyroid tumors) reported at least three times.
Report a problemFND-4071663703
04HumanObservational studySafety outcome
In European pharmacovigilance reports for weight management, semaglutide was associated with higher reported vomiting frequency; the abstract did not specify the original reporting reference.
In plain wordsIn weight-management safety reports, semaglutide was linked to higher vomiting reporting; the exact reporting comparison was unstated.
Peptide
Semaglutide
Outcome
Increasevomiting reporting frequency
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
Disproportionality analysis revealed that liraglutide was associated with a higher reporting frequency of pancreatitis, gallbladder disorders, and thyroid tumors, while semaglutide showed a greater likelihood of vomiting and abdominal pain.
3 context sentences(design, population, supporting numbers)
Summary · context
A retrospective case-non-case study was conducted using data from the EudraVigilance database.
Summary · context
All cases involving liraglutide or semaglutide used for weight management and collected in the database between January 2018 and December 2023 were analyzed.
Summary · context
Disproportionality analysis was performed to assess the reporting odds ratios for events of interest (gastrointestinal events, pancreatitis, gallbladders disorders, psychiatric events, and gallbladder, pancreatic or thyroid tumors) reported at least three times.
Report a problemFND-4071663704
05HumanObservational studySafety outcome
In European pharmacovigilance reports for weight management, semaglutide was associated with higher reported abdominal pain frequency; the abstract did not specify the original reporting reference.
In plain wordsIn weight-management safety reports, semaglutide was linked to higher abdominal pain reporting; the exact reporting comparison was unstated.
Peptide
Semaglutide
Outcome
Increaseabdominal pain reporting frequency
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
Disproportionality analysis revealed that liraglutide was associated with a higher reporting frequency of pancreatitis, gallbladder disorders, and thyroid tumors, while semaglutide showed a greater likelihood of vomiting and abdominal pain.
3 context sentences(design, population, supporting numbers)
Summary · context
A retrospective case-non-case study was conducted using data from the EudraVigilance database.
Summary · context
All cases involving liraglutide or semaglutide used for weight management and collected in the database between January 2018 and December 2023 were analyzed.
Summary · context
Disproportionality analysis was performed to assess the reporting odds ratios for events of interest (gastrointestinal events, pancreatitis, gallbladders disorders, psychiatric events, and gallbladder, pancreatic or thyroid tumors) reported at least three times.
Report a problemFND-4071663705

Studies that did not test the peptide alone20

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

06HumanNot a test of Liraglutide aloneObservational studySafety outcome
In pooled European weight-management reports involving liraglutide or semaglutide, no significant other common gastrointestinal events difference was reported; the exact original reporting comparison was unspecified.
In plain wordsIn weight-management reports involving liraglutide or semaglutide, other gastrointestinal events showed no significant difference; the exact reporting comparison was unspecified.
Peptide
Liraglutide
Outcome
No significant changeother common gastrointestinal event reporting frequency
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Source sentences
Summary
No significant differences were found for other common gastrointestinal events, pancreatic tumors, depression, or suicidal ideation.
3 context sentences(design, population, supporting numbers)
Summary · context
A retrospective case-non-case study was conducted using data from the EudraVigilance database.
Summary · context
All cases involving liraglutide or semaglutide used for weight management and collected in the database between January 2018 and December 2023 were analyzed.
Summary · context
Disproportionality analysis was performed to assess the reporting odds ratios for events of interest (gastrointestinal events, pancreatitis, gallbladders disorders, psychiatric events, and gallbladder, pancreatic or thyroid tumors) reported at least three times.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4071663706
07HumanNot a test of Liraglutide aloneObservational studySafety outcome
In pooled European weight-management reports involving liraglutide or semaglutide, no significant pancreatic tumors difference was reported; the exact original reporting comparison was unspecified.
In plain wordsIn weight-management reports involving liraglutide or semaglutide, pancreatic tumors showed no significant difference; the exact reporting comparison was unspecified.
Peptide
Liraglutide
Outcome
No significant changepancreatic tumor reporting frequency
Study
n: not reported in source
Outcome group
Adverse events · Cancer
Source sentences
Summary
No significant differences were found for other common gastrointestinal events, pancreatic tumors, depression, or suicidal ideation.
3 context sentences(design, population, supporting numbers)
Summary · context
A retrospective case-non-case study was conducted using data from the EudraVigilance database.
Summary · context
All cases involving liraglutide or semaglutide used for weight management and collected in the database between January 2018 and December 2023 were analyzed.
Summary · context
Disproportionality analysis was performed to assess the reporting odds ratios for events of interest (gastrointestinal events, pancreatitis, gallbladders disorders, psychiatric events, and gallbladder, pancreatic or thyroid tumors) reported at least three times.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4071663707
08HumanNot a test of Liraglutide aloneObservational studySafety outcome
In pooled European weight-management reports involving liraglutide or semaglutide, no significant depression difference was reported; the exact original reporting comparison was unspecified.
In plain wordsIn weight-management reports involving liraglutide or semaglutide, depression showed no significant difference; the exact reporting comparison was unspecified.
Peptide
Liraglutide
Outcome
No significant changedepression reporting frequency
Study
n: not reported in source
Outcome group
Adverse events · Mental health and mood
Source sentences
Summary
No significant differences were found for other common gastrointestinal events, pancreatic tumors, depression, or suicidal ideation.
3 context sentences(design, population, supporting numbers)
Summary · context
A retrospective case-non-case study was conducted using data from the EudraVigilance database.
Summary · context
All cases involving liraglutide or semaglutide used for weight management and collected in the database between January 2018 and December 2023 were analyzed.
Summary · context
Disproportionality analysis was performed to assess the reporting odds ratios for events of interest (gastrointestinal events, pancreatitis, gallbladders disorders, psychiatric events, and gallbladder, pancreatic or thyroid tumors) reported at least three times.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4071663708
09HumanNot a test of Liraglutide aloneObservational studySafety outcome
In pooled European weight-management reports involving liraglutide or semaglutide, no significant suicidal ideation difference was reported; the exact original reporting comparison was unspecified.
In plain wordsIn weight-management reports involving liraglutide or semaglutide, suicidal ideation showed no significant difference; the exact reporting comparison was unspecified.
Peptide
Liraglutide
Outcome
No significant changesuicidal ideation reporting frequency
Study
n: not reported in source
Outcome group
Adverse events · Mental health and mood
Source sentences
Summary
No significant differences were found for other common gastrointestinal events, pancreatic tumors, depression, or suicidal ideation.
3 context sentences(design, population, supporting numbers)
Summary · context
A retrospective case-non-case study was conducted using data from the EudraVigilance database.
Summary · context
All cases involving liraglutide or semaglutide used for weight management and collected in the database between January 2018 and December 2023 were analyzed.
Summary · context
Disproportionality analysis was performed to assess the reporting odds ratios for events of interest (gastrointestinal events, pancreatitis, gallbladders disorders, psychiatric events, and gallbladder, pancreatic or thyroid tumors) reported at least three times.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4071663709
10HumanNot a test of Liraglutide aloneObservational studySafety outcome
In pooled European pharmacovigilance reports involving liraglutide or semaglutide for weight management, most reported adverse events were non-serious.
In plain wordsIn pooled weight-management safety reports involving liraglutide or semaglutide, most adverse events were not serious.
Peptide
Liraglutide
Outcome
Not applicablenon-serious adverse events
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Source sentences
Summary
Most reported AEs were not-serious.
2 context sentences(design, population, supporting numbers)
Summary · context
A retrospective case-non-case study was conducted using data from the EudraVigilance database.
Summary · context
All cases involving liraglutide or semaglutide used for weight management and collected in the database between January 2018 and December 2023 were analyzed.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4071663710
11HumanNot a test of Semaglutide aloneObservational studySafety outcome
In pooled European pharmacovigilance reports involving liraglutide or semaglutide for weight management, most reported adverse events were non-serious.
In plain wordsIn pooled weight-management safety reports involving liraglutide or semaglutide, most adverse events were not serious.
Peptide
Semaglutide
Outcome
Not applicablenon-serious adverse events
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Source sentences
Summary
Most reported AEs were not-serious.
2 context sentences(design, population, supporting numbers)
Summary · context
A retrospective case-non-case study was conducted using data from the EudraVigilance database.
Summary · context
All cases involving liraglutide or semaglutide used for weight management and collected in the database between January 2018 and December 2023 were analyzed.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4071663711
12HumanNot a test of Liraglutide aloneObservational studySafety outcome
In pooled European pharmacovigilance reports involving liraglutide or semaglutide for weight management, gastrointestinal events were the most common adverse events.
In plain wordsIn pooled weight-management safety reports involving liraglutide or semaglutide, stomach and bowel events were most common.
Peptide
Liraglutide
Outcome
Not applicablegastrointestinal adverse events
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Source sentences
Summary
Gastrointestinal events were the most common, with nausea, vomiting, and diarrhea leading the list.
2 context sentences(design, population, supporting numbers)
Summary · context
A retrospective case-non-case study was conducted using data from the EudraVigilance database.
Summary · context
All cases involving liraglutide or semaglutide used for weight management and collected in the database between January 2018 and December 2023 were analyzed.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4071663712
13HumanNot a test of Semaglutide aloneObservational studySafety outcome
In pooled European pharmacovigilance reports involving liraglutide or semaglutide for weight management, gastrointestinal events were the most common adverse events.
In plain wordsIn pooled weight-management safety reports involving liraglutide or semaglutide, stomach and bowel events were most common.
Peptide
Semaglutide
Outcome
Not applicablegastrointestinal adverse events
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Source sentences
Summary
Gastrointestinal events were the most common, with nausea, vomiting, and diarrhea leading the list.
2 context sentences(design, population, supporting numbers)
Summary · context
A retrospective case-non-case study was conducted using data from the EudraVigilance database.
Summary · context
All cases involving liraglutide or semaglutide used for weight management and collected in the database between January 2018 and December 2023 were analyzed.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4071663713
14HumanNot a test of Liraglutide aloneObservational studySafety outcome
In pooled European pharmacovigilance reports involving liraglutide or semaglutide for weight management, nausea was among the most common gastrointestinal adverse events.
In plain wordsIn pooled weight-management safety reports involving liraglutide or semaglutide, nausea was among the most common stomach or bowel events.
Peptide
Liraglutide
Outcome
Not applicablenausea reports
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Source sentences
Summary
Gastrointestinal events were the most common, with nausea, vomiting, and diarrhea leading the list.
2 context sentences(design, population, supporting numbers)
Summary · context
A retrospective case-non-case study was conducted using data from the EudraVigilance database.
Summary · context
All cases involving liraglutide or semaglutide used for weight management and collected in the database between January 2018 and December 2023 were analyzed.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4071663714
15HumanNot a test of Semaglutide aloneObservational studySafety outcome
In pooled European pharmacovigilance reports involving liraglutide or semaglutide for weight management, nausea was among the most common gastrointestinal adverse events.
In plain wordsIn pooled weight-management safety reports involving liraglutide or semaglutide, nausea was among the most common stomach or bowel events.
Peptide
Semaglutide
Outcome
Not applicablenausea reports
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Source sentences
Summary
Gastrointestinal events were the most common, with nausea, vomiting, and diarrhea leading the list.
2 context sentences(design, population, supporting numbers)
Summary · context
A retrospective case-non-case study was conducted using data from the EudraVigilance database.
Summary · context
All cases involving liraglutide or semaglutide used for weight management and collected in the database between January 2018 and December 2023 were analyzed.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4071663715
16HumanNot a test of Liraglutide aloneObservational studySafety outcome
In pooled European pharmacovigilance reports involving liraglutide or semaglutide for weight management, vomiting was among the most common gastrointestinal adverse events.
In plain wordsIn pooled weight-management safety reports involving liraglutide or semaglutide, vomiting was among the most common stomach or bowel events.
Peptide
Liraglutide
Outcome
Not applicablevomiting reports
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Source sentences
Summary
Gastrointestinal events were the most common, with nausea, vomiting, and diarrhea leading the list.
2 context sentences(design, population, supporting numbers)
Summary · context
A retrospective case-non-case study was conducted using data from the EudraVigilance database.
Summary · context
All cases involving liraglutide or semaglutide used for weight management and collected in the database between January 2018 and December 2023 were analyzed.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4071663716
17HumanNot a test of Semaglutide aloneObservational studySafety outcome
In pooled European pharmacovigilance reports involving liraglutide or semaglutide for weight management, vomiting was among the most common gastrointestinal adverse events.
In plain wordsIn pooled weight-management safety reports involving liraglutide or semaglutide, vomiting was among the most common stomach or bowel events.
Peptide
Semaglutide
Outcome
Not applicablevomiting reports
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Source sentences
Summary
Gastrointestinal events were the most common, with nausea, vomiting, and diarrhea leading the list.
2 context sentences(design, population, supporting numbers)
Summary · context
A retrospective case-non-case study was conducted using data from the EudraVigilance database.
Summary · context
All cases involving liraglutide or semaglutide used for weight management and collected in the database between January 2018 and December 2023 were analyzed.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4071663717
18HumanNot a test of Liraglutide aloneObservational studySafety outcome
In pooled European pharmacovigilance reports involving liraglutide or semaglutide for weight management, diarrhea was among the most common gastrointestinal adverse events.
In plain wordsIn pooled weight-management safety reports involving liraglutide or semaglutide, diarrhea was among the most common stomach or bowel events.
Peptide
Liraglutide
Outcome
Not applicablediarrhea reports
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Source sentences
Summary
Gastrointestinal events were the most common, with nausea, vomiting, and diarrhea leading the list.
2 context sentences(design, population, supporting numbers)
Summary · context
A retrospective case-non-case study was conducted using data from the EudraVigilance database.
Summary · context
All cases involving liraglutide or semaglutide used for weight management and collected in the database between January 2018 and December 2023 were analyzed.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4071663718
19HumanNot a test of Semaglutide aloneObservational studySafety outcome
In pooled European pharmacovigilance reports involving liraglutide or semaglutide for weight management, diarrhea was among the most common gastrointestinal adverse events.
In plain wordsIn pooled weight-management safety reports involving liraglutide or semaglutide, diarrhea was among the most common stomach or bowel events.
Peptide
Semaglutide
Outcome
Not applicablediarrhea reports
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Source sentences
Summary
Gastrointestinal events were the most common, with nausea, vomiting, and diarrhea leading the list.
2 context sentences(design, population, supporting numbers)
Summary · context
A retrospective case-non-case study was conducted using data from the EudraVigilance database.
Summary · context
All cases involving liraglutide or semaglutide used for weight management and collected in the database between January 2018 and December 2023 were analyzed.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4071663719
20HumanNot a test of Liraglutide aloneObservational studySafety outcome
In pooled European pharmacovigilance reports involving liraglutide or semaglutide for weight management, two events were related to gallbladder tumors.
In plain wordsIn pooled weight-management safety reports involving liraglutide or semaglutide, two reports concerned gallbladder tumors.
Peptide
Liraglutide
Outcome
Not applicablegallbladder tumor reports
Study
n: not reported in source
Outcome group
Adverse events · Cancer
Source sentences
Summary
Two events were related to gallbladder tumors.
2 context sentences(design, population, supporting numbers)
Summary · context
A retrospective case-non-case study was conducted using data from the EudraVigilance database.
Summary · context
All cases involving liraglutide or semaglutide used for weight management and collected in the database between January 2018 and December 2023 were analyzed.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4071663720
21HumanNot a test of Semaglutide aloneObservational studySafety outcome
In pooled European pharmacovigilance reports involving liraglutide or semaglutide for weight management, two events were related to gallbladder tumors.
In plain wordsIn pooled weight-management safety reports involving liraglutide or semaglutide, two reports concerned gallbladder tumors.
Peptide
Semaglutide
Outcome
Not applicablegallbladder tumor reports
Study
n: not reported in source
Outcome group
Adverse events · Cancer
Source sentences
Summary
Two events were related to gallbladder tumors.
2 context sentences(design, population, supporting numbers)
Summary · context
A retrospective case-non-case study was conducted using data from the EudraVigilance database.
Summary · context
All cases involving liraglutide or semaglutide used for weight management and collected in the database between January 2018 and December 2023 were analyzed.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4071663721
22HumanNot a test of Semaglutide aloneObservational studySafety outcome
In pooled European weight-management reports involving liraglutide or semaglutide, no significant other common gastrointestinal events difference was reported; the exact original reporting comparison was unspecified.
In plain wordsIn weight-management reports involving liraglutide or semaglutide, other gastrointestinal events showed no significant difference; the exact reporting comparison was unspecified.
Peptide
Semaglutide
Outcome
No significant changeother common gastrointestinal events reporting frequency
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Source sentences
Summary
No significant differences were found for other common gastrointestinal events, pancreatic tumors, depression, or suicidal ideation.
3 context sentences(design, population, supporting numbers)
Summary · context
A retrospective case-non-case study was conducted using data from the EudraVigilance database.
Summary · context
All cases involving liraglutide or semaglutide used for weight management and collected in the database between January 2018 and December 2023 were analyzed.
Summary · context
Disproportionality analysis was performed to assess the reporting odds ratios for events of interest (gastrointestinal events, pancreatitis, gallbladders disorders, psychiatric events, and gallbladder, pancreatic or thyroid tumors) reported at least three times.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4071663722
23HumanNot a test of Semaglutide aloneObservational studySafety outcome
In pooled European weight-management reports involving liraglutide or semaglutide, no significant pancreatic tumors difference was reported; the exact original reporting comparison was unspecified.
In plain wordsIn weight-management reports involving liraglutide or semaglutide, pancreatic tumors showed no significant difference; the exact reporting comparison was unspecified.
Peptide
Semaglutide
Outcome
No significant changepancreatic tumors reporting frequency
Study
n: not reported in source
Outcome group
Adverse events · Cancer
Source sentences
Summary
No significant differences were found for other common gastrointestinal events, pancreatic tumors, depression, or suicidal ideation.
3 context sentences(design, population, supporting numbers)
Summary · context
A retrospective case-non-case study was conducted using data from the EudraVigilance database.
Summary · context
All cases involving liraglutide or semaglutide used for weight management and collected in the database between January 2018 and December 2023 were analyzed.
Summary · context
Disproportionality analysis was performed to assess the reporting odds ratios for events of interest (gastrointestinal events, pancreatitis, gallbladders disorders, psychiatric events, and gallbladder, pancreatic or thyroid tumors) reported at least three times.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4071663723
24HumanNot a test of Semaglutide aloneObservational studySafety outcome
In pooled European weight-management reports involving liraglutide or semaglutide, no significant depression difference was reported; the exact original reporting comparison was unspecified.
In plain wordsIn weight-management reports involving liraglutide or semaglutide, depression showed no significant difference; the exact reporting comparison was unspecified.
Peptide
Semaglutide
Outcome
No significant changedepression reporting frequency
Study
n: not reported in source
Outcome group
Adverse events · Mental health and mood
Source sentences
Summary
No significant differences were found for other common gastrointestinal events, pancreatic tumors, depression, or suicidal ideation.
3 context sentences(design, population, supporting numbers)
Summary · context
A retrospective case-non-case study was conducted using data from the EudraVigilance database.
Summary · context
All cases involving liraglutide or semaglutide used for weight management and collected in the database between January 2018 and December 2023 were analyzed.
Summary · context
Disproportionality analysis was performed to assess the reporting odds ratios for events of interest (gastrointestinal events, pancreatitis, gallbladders disorders, psychiatric events, and gallbladder, pancreatic or thyroid tumors) reported at least three times.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4071663724
25HumanNot a test of Semaglutide aloneObservational studySafety outcome
In pooled European weight-management reports involving liraglutide or semaglutide, no significant suicidal ideation difference was reported; the exact original reporting comparison was unspecified.
In plain wordsIn weight-management reports involving liraglutide or semaglutide, suicidal ideation showed no significant difference; the exact reporting comparison was unspecified.
Peptide
Semaglutide
Outcome
No significant changesuicidal ideation reporting frequency
Study
n: not reported in source
Outcome group
Adverse events · Mental health and mood
Source sentences
Summary
No significant differences were found for other common gastrointestinal events, pancreatic tumors, depression, or suicidal ideation.
3 context sentences(design, population, supporting numbers)
Summary · context
A retrospective case-non-case study was conducted using data from the EudraVigilance database.
Summary · context
All cases involving liraglutide or semaglutide used for weight management and collected in the database between January 2018 and December 2023 were analyzed.
Summary · context
Disproportionality analysis was performed to assess the reporting odds ratios for events of interest (gastrointestinal events, pancreatitis, gallbladders disorders, psychiatric events, and gallbladder, pancreatic or thyroid tumors) reported at least three times.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4071663725

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 2
9 Oct 2026, 03:06 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.